European Oncology Biotechs Start Ominous ‘Strategic Reviews’ To Survive

 
• By Kevin Grogan

Norwegian firm BerGenBio, Lava of the Netherlands and Poland’s Ryvu are all weighing up diverse options to maximize shareholder value and stay alive, including licensing agreements and mergers.

Europe Map Plate Broken
• Source: Shutterstock

More from Strategy

More from Deals